Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA “Best Start-Up” Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

laotiantimes.com · health
Full story

Paradigm Therapeutics, Inc. received a nomination for the 2026 Prix Galien USA Best Start-Up award for the second year in a row. The nomination is for SD-101, also known as Zorblesia. This topical therapy is designed to treat wounds and lesions across the entire skin surface for all subtypes of Epidermolysis Bullosa.

SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping the future of healthcare and medical innovation. MOUNT PLEASANT, S.C., Oct. 14, […]

Read full article → Compare